Pharma Industry News

A collection of Pharma latest news, analysis and best practices from top business influencers and the world's most trustworthy sources.

thestandard.com.hk - The Standard 英文虎報 - SFC orders biotech firm Cloudbreak Pharma to suspend trading
SFC orders biotech firm Cloudbreak Pharma to suspend trading
The Standard

The Securities and Futures Commission has directed the stock exchange of Hong Kong to suspend all dealing in the shares of Cloudbreak Pharma (2592), effective at 9:00 am on Thursday. SCROLL TO CONTINUE WITH CONTENT The regulatory action was…

globenewswire.com - Zealand Pharma - Zealand Pharma to participate in the Morgan Stanley 24th Annual Global Healthcare Conference
Zealand Pharma to participate in the Morgan Stanley 24th Annual Global Healthcare Conference
GlobeNewswire

Press release – No. 15 / 2026 Zealand Pharma to participate in the Morgan Stanley 24 Annual Global Healthcare Conference Copenhagen, Denmark, September 9, 2026 - Zealand Pharma A/S (Nasdaq: ZEAL) (CVR-no. 20045078), a biotechnology company…

newswire.ca - Innocan Pharma Announces Private Placement of Units
Innocan Pharma Announces Private Placement of Units
CNW

HERZLIYA, Israel and CALGARY, Alberta, Sept. 9, 2026 /CNW/ -- Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTC: INNPF) (the 'Company' or 'Innocan') is pleased to announce that it intends to complete a private placement of up to 535,000 units…

seekingalpha.com - Galzus Research - Urogen Pharma: Upside After Bladder Cancer Launch (NASDAQ:URGN)
Urogen Pharma: Upside After Bladder Cancer Launch (NASDAQ:URGN)
Seeking Alpha

UroGen Pharma Ltd. has transitioned into a commercial-stage biopharma, driven by strong adoption of Zusduri for recurrent non-muscle-invasive bladder cancer. Zusduri achieved an 80% complete response rate in the ENVISION trial, with a 64.5% chance…

seekingalpha.com - Wolf Report - Zealand Pharma: A Play On Medicine Discovery, But Too Expensive Right Now (OTCMKTS:ZLDPF)
Zealand Pharma: A Play On Medicine Discovery, But Too Expensive Right Now (OTCMKTS:ZLDPF)
Seeking Alpha

Zealand Pharma (ZEAL) offers a differentiated obesity drug pipeline, notably Petrelintide, with strong tolerability and strategic Roche collaboration. ZEAL's Roche deal secures $1.65B upfront plus substantial milestones, 50% profit share in US/EU…

thehindubusinessline.com - GLP-1 boom pushes pharma companies deeper into wellness, nutraceuticals
GLP-1 boom pushes pharma companies deeper into wellness, nutraceuticals
BusinessLine

The rapid growth of GLP-1 drugs for weight loss is prompting pharmaceutical companies to look beyond the medicines themselves, with wellness and nutraceuticals emerging as adjacent opportunities in the fast-growing weight-management market.

marketbeat.com - Innate Pharma (IPHA) Projected to Post Quarterly Earnings on Thursday
Innate Pharma (IPHA) Projected to Post Quarterly Earnings on Thursday
MarketBeat

Innate Pharma (NASDAQ:IPHA - Get Free Report) will likely be announcing its Q2 2026 results before the market opens on Thursday, September 17th. Analysts expect Innate Pharma to announce earnings of ($0.2946) per share and revenue of $6.3530…

marketbeat.com - NewAmsterdam Pharma (NASDAQ:NAMS) Reaches New 52-Week Low on Insider Selling
NewAmsterdam Pharma (NASDAQ:NAMS) Reaches New 52-Week Low on Insider Selling
MarketBeat

NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS - Get Free Report)'s share price hit a new 52-week low during trading on Thursday after an insider sold shares in the company. The stock traded as low as $22.34 and last traded at $22.79, with a volume…

marketbeat.com - John Smither Sells 1,600 Shares of NewAmsterdam Pharma (NASDAQ:NAMS) Stock
John Smither Sells 1,600 Shares of NewAmsterdam Pharma (NASDAQ:NAMS) Stock
MarketBeat

NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS - Get Free Report) Director John Smither sold 1,600 shares of the firm's stock in a transaction dated Friday, September 4th. The shares were sold at an average price of $25.32, for a total transaction…

cnbc.com - Jim Cramer - Jim Cramer's top 10 things to watch in the stock market Wednesday
Jim Cramer's top 10 things to watch in the stock market Wednesday
CNBC

My top 10 things to watch Wednesday, Sept. 9 1. Back to $100 a barrel we go on Brent crude. Stock futures, predictably, are lower this morning. It will be very hard for stocks to rally facing $100 oil this time because of the huge drawdowns of the…

marketbeat.com - Bank of New York Mellon Corp Acquires New Shares in Avalyn Pharma Inc. $AVLN
Bank of New York Mellon Corp Acquires New Shares in Avalyn Pharma Inc. $AVLN
MarketBeat

Bank of New York Mellon Corp bought a new stake in Avalyn Pharma Inc. (NASDAQ:AVLN - Free Report) in the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm bought 40,140 shares of the…

rediff.com - Nandita Malik - Indian Stock Markets Flat: Crude Oil Prices, Geopolitical Tensions Impact Sensex, Nifty
Indian Stock Markets Flat: Crude Oil Prices, Geopolitical Tensions Impact Sensex, Nifty
Rediff.com

Indian benchmark indices, Sensex and Nifty, are trading flat in early deals as elevated crude oil prices above $100 per barrel and persistent geopolitical tensions continue to dampen investor risk appetite. Indian benchmark indices, Sensex and…

marketbeat.com - BridgeBio Pharma, Inc. $BBIO Shares Bought by Squarepoint Ops LLC
BridgeBio Pharma, Inc. $BBIO Shares Bought by Squarepoint Ops LLC
MarketBeat

Squarepoint Ops LLC boosted its holdings in BridgeBio Pharma, Inc. (NASDAQ:BBIO - Free Report) by 114.2% during the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional…

thehindu.com - Pti - Markets trade flat in early deals amid elevated crude oil prices, geopolitical tensions
Markets trade flat in early deals amid elevated crude oil prices, geopolitical tensions
The Hindu

Market benchmark indices Sensex and Nifty were trading on a flat note in early deals on Thursday (September 10, 2026) as elevated crude oil prices above $100-per-barrel mark, amid persistent geopolitical tensions, kept risk appetite subdued. The…

seekingalpha.com - High Alpha Professor - C.H. Robinson: The $604 Million Verdict Looks Bigger Than The Economic Risk (NASDAQ:CHRW)
C.H. Robinson: The $604 Million Verdict Looks Bigger Than The Economic Risk (NASDAQ:CHRW)
Seeking Alpha

C.H. Robinson Worldwide faces headline risk from a $604 million verdict, but insurance and fault allocation significantly limit direct financial exposure. Montgomery v. Caribe Transport II increases legal risk for brokers, but the true impact will…

Receive a Daily briefing on Pharma Industry News

Get Started